オプションチェーンは、Tonix Pharmaceuticalsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Tonix Pharmaceuticalsの市場センチメントを評価します。.

Tonix Pharmaceuticals (NASDAQ:TNXP) 株価情報, オプションチェーン

Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

News

Pre-Market Outlook

Markets

Movers

AYRO

CLDI

CLNN

GDHG

GOOGL

MREO

OBLG

ORCL

PETS

PIXY

SRFM

THMO

TNXP

WLGS

オラクル・コーポレーション (NYSE:ORCL) の株価は、同社が第4四半期決算を発表した後、本日のプレマーケット取引で急騰しました。オラクルは自社の2021年4月～6月期決算において、予想を下回る決算を発表しました。同社は、アルファベット（Alphabet Inc）（NASDAQ:GOOGL）（NASDAQ:GOOG）のGoogle Cloudと提携することも発表しました。

オラクルの株価9%上昇の理由

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals Holding Corp

<h3>Gainers</h3>
<ul>
<li>Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) stock rose 144.9% to $1.55 during Wednesday's pre-market session. The company's market cap stands at $221.2 million. </li>
<li>Forte Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>) shares moved upwards by 76.53% to $10.46. The company's market cap stands at $15.2 million. The company's, Q3 earnings came out 4 days ago. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) stock rose 72.36% to $0.39. The company's market cap stands at $5.6 million. As per the news, the Q3 earnings report came out 4 days ago. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares moved upwards by 57.59% to $0.26. The market value of their outstanding shares is at $47.9 million. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) shares rose 21.13% to $7.05. The company's market cap stands at $15.3 million. As per the press release, Q3 earnings came out 4 days ago. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares moved upwards by 19.85% to $1.63. The company's market cap stands at $278.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lineage Cell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LCTX#AMEX">LCTX</a>) shares declined by 19.7% to $0.72 during Wednesday's pre-market session. The company's market cap stands at $136.9 million. As per the press release, Q3 earnings came out 4 days ago. </li>
<li>Apollomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) shares declined by 17.23% to $0.14. The company's market cap stands at $14.9 million. </li>
<li>BrightSpring Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTSGU#NASDAQ">BTSGU</a>) stock declined by 16.86% to $56.38. </li>
<li>Oncology Institute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) stock fell 15.56% to $0.15. The market value of their outstanding shares is at $11.4 million. </li>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares declined by 15.35% to $0.93. The market value of their outstanding shares is at $35.2 million. As per the news, the Q3 earnings report came out 4 days ago. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares decreased by 13.93% to $0.1. The market value of their outstanding shares is at $8.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APLM

BTSGU

EYEN

FBRX

HCWB

LCTX

SLXN

TVGN

XCUR

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Shares of Keysight Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) rose sharply in today's pre-market trading reported <a href="https://www.benzinga.com/news/earnings/24/11/42075636/keysight-technologies-stock-jumps-on-q4-earnings-revenue-beat-eps-beat-confidence-in-our-ability-to-outperform">better-than-expected earnings for its fourth quarter.</a>
Keysight reported quarterly earnings of $1.65 per share which beat the analyst consensus estimate of $1.57. The company reported quarterly sales of $1.287 billion which beat the analyst consensus estimate of $1.258 billion.
The company said it sees first-quarter revenue of $1.265 billion to $1.285 billion and adjusted earnings of $1.65 to $1.71 per share.
Keysight shares jumped 9.3% to $166.20 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) gained 63.6% to $0.2663 in pre-market trading after jumping 22% on Tuesday.</li>
<li>Nauticus Robotics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) rose 59.3% to $1.45 in pre-market trading after the company entered into strategic collaboration with SeaTrepid to integrate and test its ToolKITT software on remotely operated vehicles.</li>
<li>Tevogen Bio Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) gained 41.2% to $1.92 in pre-market trading following third-quarter results.</li>
<li>Digital Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) gained 30.7% to $0.1524 in pre-market trading after jumping around 18% on Tuesday.</li>
<li>JX Luxventure Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JXJT#NASDAQ">JXJT</a>) gained 26.2% to $1.64 in pre-market trading after declining around 12% on Tuesday.</li>
<li>KORE Group Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KORE#NYSE">KORE</a>) gained 25.1% to $2.29 in pre-market trading after the company reported better-than-expected quarterly sales results.</li>
<li>Algorhythm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIME#NASDAQ">RIME</a>) gained 23.4% to $0.3150 in pre-market trading after reporting third-quarter results.</li>
<li>Hoth Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>) climbed 22.2% to $0.9993 in pre-market trading after the company was granted U.S. Patent No. 12,144,815 titled &#8220;Use of Aprepitant for Treating Alzheimer&#8217;s Disease.&#8221;</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) gained 20.8% to $5.55 in pre-market trading. Kingsoft Cloud, on Tuesday, reported a fiscal third-quarter 2024 revenue of 1.89 billion Chinese yuan ($268.7 million), up by 16.0% year-on-year, beating the analyst consensus estimate of $247.46 million.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>PainReform Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRFX#NASDAQ">PRFX</a>) shares tumbled 26.4% to $1.03 in pre-market trading after jumping 162% on Tuesday. The company announced a 1-for-4 reverse stock split.</li>
<li>X3 Holdings Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTKG#NASDAQ">XTKG</a>) fell 27.4% to $0.1050 in pre-market trading. XTKG announced a 1-for-20 share consolidation.</li>
<li>Solidion Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STI#NASDAQ">STI</a>) shares fell 21.2% to $0.5003 in pre-market trading following third-quarter results.</li>
<li>Volato Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#NYSE">SOAR</a>) declined 16.7% to $0.3912 in pre-market trading after jumping 123% on Tuesday. Volato Group, on Monday, reported a year-over-year increase in third-quarter financial results.</li>
<li>HCW Biologics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares fell 16.6% to $0.9180 in pre-market trading after dipping 11% on Tuesday. The company announced a $6.9 million direct offering and private placement.</li>
<li>Powell Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>) dipped 15.4% to $264.00 in pre-market trading after the company reported worse-than-expected fourth-quarter revenue results.</li>
<li>Destiny Tech100 Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXYZ#NASDAQ">DXYZ</a>) shares dipped 13.4% to $39.18 in pre-market trading after jumping 24% on Tuesday.</li>
<li>Workhorse Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKHS#NASDAQ">WKHS</a>) fell 13.1% to $1.06 in pre-market trading after posting quarterly results.</li>
<li>Silvercorp Metals Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SVM#NYSE">SVM</a>) fell 11.3% to $3.59 in pre-market trading after the company announced a $130 million convertible senior notes offering.</li>
<li>QuidelOrtho Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) fell 6.7% to $36.01 in today's pre-market trading after the company announced the pricing of secondary offering of common stock by the Carlyle Group.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/11/42069785/wall-streets-most-accurate-analysts-weigh-in-on-3-defensive-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Defensive Stocks With Over 5% Dividend Yields</a></li>
</ul>

Trading Ideas

DBGI

DXYZ

HOTH

JXJT

KEYS

KITT

KORE

POWL

PRFX

QDEL

RIME

SOAR

WKHS

XTKG

Why Keysight Technologies Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket

The World Health Organization (WHO) declared the spread of new Clade Ib Mpox a public health emergency of international concern (PHEIC): Second Mpox-related WHO PHEIC declaration in two years
Clade Ib Mpox cases detected in 16 African countries and outside of Africa, in Sweden, Thailand, Singapore, India, Germany and England
Single-dose mpox vaccines with durable protection may be required to address global health emergency
TNX-801 was shown to be more than 10- to 1,000-fold more attenuated (or less virulent) compared to the older vaccinia smallpox vaccines: Tolerability of TNX‐801 vaccination in immune-compromised animal models supports clinical development

Biotech

General

Tonix Pharmaceuticals Publishes Peer-Reviewed Publication In mSphere Journal Highlighting Tolerability Of its Single-Dose Mpox And Smallpox Vaccine Candidate TNX-801, In Immune-Compromised Animals

Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(2.93) by 92.15 percent. The company reported quarterly sales of $2.80 million which missed the analyst consensus estimate of $3.08 million by 9.19 percent. This is a 29.81 percent decrease over sales of $3.99 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Tonix Pharmaceuticals Q3 2024 GAAP EPS $(0.23) Beats $(2.93) Estimate, Sales $2.80M Miss $3.08M Estimate

https://www.reuters.com/world/uk/uk-detects-two-more-cases-new-mpox-variant-2024-11-04/#:~:text=LONDON%2C%20Nov%204%20(Reuters),to%20the%20population%20remained%20low.

Macro Notification

AEMD

CMRX

GOVX

MRNA

VRAX

'UK detects two more cases of new mpox variant' - Reuters

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801: Says New Data Show Tolerability And No Evidence Of Spreading To Blood Or Tissues Even At High Doses Of Tonix's Attenuated Live-virus, Minimally Replicating Vaccine Candidate Tnx-801 In Immunocompromised Animals

APDN

BWVI

WHO Expands Emergency Use List For Mpox Diagnostics, Adds Cepheid's Xpert Mpox PCR Test And Roche's Cobas MPXV Assay As PCR-Based Gold Standard Options

Tonix Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NYSE">TNXP</a>) short percent of float has risen 179.25% since its last report. The company recently reported that it has 8.29 million shares sold short, which is 5.92% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Tonix Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729619117_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Tonix Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Tonix Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Tonix Pharmaceuticals's peer group average for short interest as a percentage of float is 2.12%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(TNXP) - Analyzing Tonix Pharmaceuticals's Short Interest

<a href="https://economictimes.indiatimes.com/news/international/world-news/new-mpox-variant-detected-in-germany-health-authority/articleshow/114463317.cms">https://economictimes.indiatimes.com/news/international/world-news/new-mpox-variant-detected-in-germany-health-authority/articleshow/114463317.cms</a>
An infection with the new mpox variant clade 1b has been detected in Germany for the first time, the Robert Koch Institute health authority said on Tuesday. &nbsp;

Reported Earlier, 'New Mpox Variant Detected In Germany: Health Authority' - The Economic Times

WIIM

Tonix Pharmaceuticals shares are trading higher after the company announced it received its first contract payment from the U.S. Department of Defense.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, received its first payment from the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense (DoD), to develop small molecule broad-spectrum antiviral agents for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. The previously announced award from DTRA is for up to $34 million over five years.

Contracts

Tonix Pharmaceuticals Receives First Contract Payment From U.S. Department Of Defense For Accelerated Development Of Broad-Spectrum Antivirals With The Defense Threat Reduction Agency; The Previously Announced Award From DTRA Is For Up To $34M Over 5-Years

Tonix Pharmaceuticals shares are trading higher after the company announced it submitted an NDA for TNX-102 SL to the FDA for fibromyalgia treatment. The non-opioid analgesic showed significant pain reduction in Phase 3 studies and received fast-track designation.

Tonix Pharmaceuticals Submits NDA For TNX-102 SL To FDA For Fibromyalgia Treatment; Non-Opioid Analgesic Shows Significant Pain Reduction In Phase 3 Studies And Receives Fast Track Designation

Tonix Pharmaceuticals Holding Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares are trading higher by 1.18% to $0.14 during Tuesday&#8217;s session after the company secured a $34 million DOD research <a href="https://www.benzinga.com/pressreleases/24/10/g41226812/tonix-pharmaceuticals-announces-ai-collaboration-with-x-chem-to-develop-broad-spectrum-antivirals">collaboration contract</a> with X-Chem.
What To Know: Tonix Pharmaceuticals announced a research collaboration with X-Chem to accelerate the development of its TNX-4200 oral broad-spectrum antiviral program. The collaboration will leverage X-Chem&#8217;s AI and machine learning technologies to optimize the drug's properties, safety and pharmacokinetics. 
The company says TNX-4200 focuses on oral CD45 phosphatase inhibitors with broad-spectrum antiviral potential, supported by a $34 million contract from the U.S. Department of Defense&#8217;s Defense Threat Reduction Agency (DTRA). 
Tonix says the DTRA funding will help advance the TNX-4200 program through key development stages, including an IND submission and a first-in-human Phase 1 trial. Tonix is meanwhile utilizing its R&amp;D facilities in Maryland for the project.
Read Also: <a href="https://www.benzinga.com/markets/equities/24/10/41222716/as-florida-prepares-for-one-of-deadliest-hurricanes-here-are-some-potential-stock-winners-and-lo">As Florida Prepares For One Of Deadliest Hurricanes, Here Are Some Potential Stock Winners And Losers From Milton Threat</a>
<h2 class="wp-block-heading">How To Buy TNXP Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>)'s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, TNXP has a 52-week high of $22.14 and a 52-week low of $0.12.

Why Tonix Pharmaceuticals (TNXP) Stock Is Moving

Tonix Pharmaceuticals shares are trading higher after the company secured a $34 million DOD research collaboration contract with X-Chem.

Tonix Pharmaceuticals Enters AI And ML Research Collaboration With X-Chem To Develop Broad-Spectrum Antivirals

Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that it has entered into an AI and ML research collaboration with X-Chem, Inc. (X-Chem), a leader in small molecule drug discovery, to accelerate development of Tonix's oral broad-spectrum antivirals.
Tonix's TNX-4200 antiviral program focuses on the development of oral CD45 phosphatase inhibitors, with broad-spectrum activity against a range of viral families. As previously disclosed, Tonix entered into a contract with the U.S. Department of Defense's Defense Threat Reduction Agency (DTRA) for up to $34 million to advance the development of Tonix's TNX-4200 broad-spectrum oral antiviral program for medical countermeasures, including an Investigational New Drug (IND) submission and a first-in-human Phase 1 clinical study.
"We are excited to enter into this research collaboration with X-Chem, which we believe will expand our capabilities, and deepen our understanding of host-targeted small molecule therapeutics for a variety of targets," said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. "With the support of X-Chem's drug discovery AI/ML technology, we expect to optimize the physicochemical properties, pharmacokinetics, and safety attributes of our drug candidates."
"We are excited to partner with Tonix in their pursuit of such important programs in human health, at the intersection of laboratory and in silico technology. This collaboration highlights how integrative work continues to leverage the creation of target-specific high-quality data to drive AI drug discovery," said Erin Davis, Ph.D., Chief Technology Officer of X-Chem."
The DTRA contract awarded to Tonix is expected to help fund and accelerate the development of the Company's lead oral host-directed TNX-4200 broad-spectrum antiviral program. The TNX-4200 program aims to reduce viral load and to allow the adaptive immune system to alert the other arms of the immune system to mount a protective response. Tonix plans to leverage previous research on phosphatase inhibitors to optimize lead compounds for therapeutic intervention of biothreat agents.
For the oral broad-spectrum antiviral programs, including TNX-4200, Tonix is utilizing its state-of-the-art research laboratory capabilities, including a Biosafety Level 3 (BSL-3) lab and an Animal Biosafety Level 3 (ABSL-3) facility at its research and development center (RDC) located in Frederick, Md., as well as experienced personnel in-house. The RDC is located in Maryland's ‘I-270 biotech corridor' and is close to the center of the U.S. biodefense research community.

Government

Regulations

Tonix Pharmaceuticals Secures $34M DOD Contract, Collaborates with X-Chem on Antiviral Research to Boost Development of Oral Antivirals Using AI and ML

Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares are trading higher Friday after the company announced the United States Patent and Trademark Office&nbsp;granted a patent covering the subcutaneous delivery of Zembrace Symtouch for treating migraines.
The Details: Issued on September 24, the patent entitled &#8216;Pharmaceutical Composition for Treating Migraine&#8217; is anticipated to provide protection into 2036.
This comes after the company launched a campaign called &#8216;Does Your Migraine Pill Work Every Time?&#8217; with the goal of informing healthcare providers and consumers about the advantages of non-oral migraine medications.
How To Buy Tonix Pharmaceuticals Stock
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>)'s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
See Also:<a href="https://www.benzinga.com/markets/cannabis/24/09/41033009/can-novo-nordisks-weight-loss-drug-ozempic-help-stem-the-devastating-addiction-crisis-new-resear"> Can Novo Nordisk&#8217;s Weight Loss Drug Ozempic Help Stem The Devastating Addiction Crisis? New Research Says Yes</a>
TNXP Price Action: At the time of writing, Tonix shares are trading 17.2% higher at 16 cents, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Akava Photo from Pixabay

What's Going On With Tonix Pharmaceuticals Stock Friday?

Tonix Pharmaceuticals shares are trading higher after the company announced the issuance of a US patent covering the subcutaneous delivery of Zembrace Symtouch for treating migraines, with market exclusivity expected into 2036.

Tonix Pharmaceuticals Announces Issuance Of U.S. Patent Covering The Subcutaneous Delivery Of FDA-approved Zembrace Symtouch To Treat Migraines; New Patent Expected To Provide Market Exclusivity Into 2036

Warning: TNXP is at high risk of performing badly

Tonix Pharma ( ($TNXP) ) has issued an update. Tonix Pharmaceuticals Holding Corp. has unveiled new data from a manuscript showing promising result...

Tonix Pharma Unveils Promising TNX-1700 Cancer Data

Reports Q3 revenue $2.822M, consensus $3.08M. "With our recent NDA submission to the U.S. Food and Drug Administration (FDA), Tonix is excited abou...

Tonix Pharmaceuticals reports Q3 EPS (23c), consensus ($2.93)

Tonix Pharmaceuticals GAAP EPS of -$0.23 beats by $3.65, revenue of $2.82M misses by $0.33M

Tonix Pharmaceuticals (TNXP) announced the publication of a paper entitled, "Recombinant Chimeric Horsepox Virus, TNX-801, is Attenuated Relative t...

Tonix Pharmaceuticals announces publication of study on tolerability of TNX-801

Tonix Pharma ( ($TNXP) ) has provided an update. Tonix Pharmaceuticals has unveiled promising data for its TNX-801 vaccine, showing it is less viru...

Tonix Pharma Reveals Promising TNX-801 Vaccine Data

First mpox case linked to African outbreak reported in U.S.

Tonix Pharmaceuticals (TNXP) presented data in a poster presentation at the ACR Convergence 2024 Annual Meeting, held November 14-19, 2024, in Wash...

Tonix Pharmaceuticals presents data, analyses of TNX-102 SL effects

BVNKF

BVNRY

CODX

RHHBF

RHHBY

SIGA

Screenshot 2024-11-13 at 11.54.41 PM

ABBV

Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments

Screenshot 2024-09-30 at 9.13.36 PM

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-18 at 12.30.33 AM

New Hope For Mpox? How TNX-801 Could Meet The WHO&#39;s Vaccine Targets For A Safer, Single-Dose Solution

Untitled design - 2024-09-04T162950.621

As Research Into Pain Accelerates, A Newly Recognized Type Of Pain Comes To The Forefront – Tonix Targets It With FDA-Fast Track-Designated TNX-102 SL

Screenshot 2024-08-23 at 3.09.59 AM

Modern Twist To Centuries-Old Smallpox Vaccine Could Be Poised To Combat Deadly Mpox Strain As WHO Declares Global Emergency

Screenshot 2024-08-01 at 5.06.20 PM

FDA Recognizes Fibromyalgia As A &#39;Serious Condition&#39; And Fast-Tracks New Drug Candidate

Screenshot 2024-07-23 at 10.19.53 PM

Beyond &#34;One Bug, One Drug&#34; – Tonix Pharmaceuticals Secures Up To $34 Million In Funding From U.S. Department Of Defense To Develop Broad-Spectrum Antiviral

Screenshot 2024-07-10 at 9.08.28 PM

AXSM

A Redux Of The Lyrica-Cymbalta Fibromyalgia War Of The 2010s May Look More Like David Vs. Goliath

Screenshot 2024-02-24 at 12.03.42 AM

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain

Press Releases

Tonix Pharmaceuticals to Present at the 2024 ThinkEquity Conference

Tonix Pharmaceuticals to Present at BIO-Europe® 2024

Health Care

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024

Tonix Pharmaceuticals Announces Research Agreement with Kenya Medical Research Institute (KEMRI) to Design, Plan and Seek Regulatory Approval for a Phase I Clinical Study of TNX-801 for Mpox in Kenya

Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights

Tonix Pharmaceuticals Announces Peer-Reviewed Publication in mSphere Journal Highlighting the Tolerability of Company's Single-Dose Mpox and Smallpox Vaccine Candidate TNX-801, in Immune-Compromised Animals

Tonix Pharmaceuticals Announces Poster Presentation at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting

Comments

Tonix Pharmaceuticals

Tonix Pharmaceuticals (TNXP) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル